Author:
Podoloff Donald A.,Advani Ranjana H.,Allred Craig,Benson Al B.,Brown Elizabeth,Burstein Harold J.,Carlson Robert W.,Coleman R. Edward,Czuczman Myron S.,Delbeke Dominique,Edge Stephen B.,Ettinger David S.,Grannis Frederic W.,Hillner Bruce E.,Hoffman John M.,Kiel Krystyna,Komaki Ritsuko,Larson Steven M.,Mankoff David A.,Rosenzweig Kenneth E.,Skibber John M.,Yahalom Joachim,Michael Yu JQ,Zelenetz Andrew D.
Abstract
The use of positron emission tomography (PET) is increasing rapidly in the United States, with the most common use of PET scanning related to oncology. It is especially useful in the staging and management of lymphoma, lung cancer, and colorectal cancer, according to a panel of expert radiologists, surgeons, radiation oncologists, nuclear medicine physicians, medical oncologists, and general internists convened in November 2006 by the National Comprehensive Cancer Network. The Task Force was charged with reviewing existing data and developing clinical recommendations for the use of PET scans in the evaluation and management of breast cancer, colon cancer, non-small cell lung cancer, and lymphoma. This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology. (JNCCN 2007;5(Suppl 1):S1–S22)